"It was good because they have a relationship with us": A qualitative study on low-threshold buprenorphine treatment at syringe services programs.

J Subst Use Addict TreatMay 20, 2026 (epub)
Clinical ResearchInfectious DiseasesOpen access

Emma McGill, Benjamin T Hayes, Teresa López-Castro et al.

✦ AI-curated · Sources linked

In 30 seconds

This qualitative study explored patient experiences with buprenorphine treatment initiated at syringe service programs (SSPs) among 12 participants following a randomized controlled trial. Key findings revealed that while onsite treatment facilitated access to buprenorphine, precipitated withdrawal was a common issue. Participants valued the supportive environment and strong relationships with healthcare providers.

Key findings

  • Onsite treatment at SSPs facilitated buprenorphine prescription but highlighted the need for additional support.
  • Precipitated withdrawal complicated buprenorphine initiation for participants in both treatment arms.
  • Participants perceived SSPs as affirming and welcoming environments for treatment.
  • Strong relationships with healthcare providers were critical for successful buprenorphine initiation.

Why it matters

Understanding patient experiences with buprenorphine treatment at SSPs can inform strategies to enhance treatment delivery and support for individuals with opioid use disorder, ultimately improving outcomes in this vulnerable population.

Source

PubMed · PMID 42155653Free full text on PubMed Central

Published in J Subst Use Addict Treat. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Infectious Diseases

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.